AI tumor board review for bladder cancer
In bladder cancer, the largest choices sit between specialties: whether to remove the bladder or keep it, and what treatment comes before surgery. A multidisciplinary board puts urology, medical oncology, radiation oncology, pathology and radiology on the same case, so those choices are weighed together.
Where the specialties split
Where the specialties at a bladder cancer tumor board split
- Bladder preservation or cystectomy
- For muscle-invasive bladder cancer (MIBC), radical cystectomy and bladder preservation with trimodality therapy, a maximal resection followed by chemoradiation, are both established options. Urology and radiation oncology can weigh them differently, and the patient’s own priorities shape the choice.
- Neoadjuvant chemotherapy for MIBC
- Cisplatin-based chemotherapy before cystectomy is standard for patients who can receive it. Who is fit for cisplatin, and what to offer patients who are not, is a frequent point of discussion between medical oncology and urology.
- BCG-unresponsive NMIBC
- When high-risk non-muscle-invasive bladder cancer (NMIBC) persists or returns after BCG, radical cystectomy remains the standard. A widening set of bladder-sparing intravesical and systemic options gives patients who decline or cannot have surgery another path, and the board weighs them against each other.
Who sits at the board
Who sits at a bladder cancer tumor board
- Urology
- Resection, intravesical therapy, cystectomy and urinary diversion.
- Medical oncology
- Chemotherapy and immunotherapy before or after surgery, and systemic therapy for advanced disease.
- Radiation oncology
- Chemoradiation as part of bladder preservation.
- Pathology
- Depth of invasion, variant histology, and whether the specimen includes muscle.
- Radiology
- How far the tumor extends, and whether it has spread.
More GU cancers
- The GU tumor board: prostate, bladder and kidney cancer
- Prostate cancer Available now.
- Kidney cancer In development.
Request access for your practice
Prostate cancer reviews are available now; bladder and kidney cancer reviews are in development. We read every request and will get back to you within two business days.
Request access